Suzano has been granted unconditional approval by the European Union for its planned $3.4 billion joint venture with Kimberly-Clark, the companies said in a European Commission statement released on Monday. The clearance marks a regulatory milestone for the transaction announced in June of last year.
As structured, the agreement provides for Suzano to acquire 51% of Kimberly-Clark's international tissue operations, a portfolio that includes the Kleenex brand. The EU decision removes a significant regulatory hurdle within the European bloc, but it does not conclude the deal process.
The transaction continues to be examined by the United Kingdom's competition watchdog. The UK review remains outstanding and may influence the timing and final conditions of the proposed combination.
Regulatory authorities have tightened scrutiny of corporate transactions in recent months. According to the European Commission statement, regulators are weighing a mix of considerations when assessing deals - including consumer interests, geopolitical factors, sustainability issues, and pressures to either restrict or permit combinations that could shape the European industrial landscape.
The tissue and paper sector itself is in the midst of consolidation. Companies in the global paper industry are responding to declining demand and persistent structural overcapacity, trends that have prompted consolidation as a strategic response to excess capacity and lower volumes.
For market participants and stakeholders, the EU approval is a material step for the Suzano-Kimberly-Clark arrangement, but the outcome of the UK review and the broader regulatory environment remain relevant uncertainties. The competitive and demand-side dynamics in the paper and consumer tissue markets will frame how the combined businesses operate post-transaction.
Below are the principal developments and outstanding considerations related to the deal:
- EU antitrust approval: Unconditional clearance from the European Commission on Monday.
- Deal structure: Suzano to acquire a 51% stake in Kimberly-Clark's international tissue business, including Kleenex.
- Remaining review: The transaction is still under assessment by the UK competition authority.
While the EU decision reduces one regulatory impediment, the process is not complete until other jurisdictions conclude their reviews. The evolving regulatory posture toward large corporate deals - which balances consumer protection, geopolitical and sustainability considerations, and industrial policy aims - will remain a factor for this transaction and others in the sector.